

**Condensed Consolidated Statement of Cash Flows – Unaudited**

For the six months ended 30 June	2021	2020
		(Restated)
	US\$m	US\$m
<b>Profit before taxation</b>		
From continuing operations	547.6	412.9
From a discontinued operation	86.4	45.3
Adjustments for:		
Finance costs	243.3	221.4
Depreciation	175.1	199.7
Amortization of other intangible assets	71.2	58.9
Provision for impairment losses	39.9	66.5
Write-down of inventories to net realizable value	7.3	11.4
Loss on changes in fair value of biological assets	2.4	10.0
Employee share-based compensation benefit expenses	1.0	1.7
Share of profits less losses of associated companies and joint ventures	(170.4)	(159.3)
Gain on deconsolidation of a discontinued operation	(66.6)	-
Gain on disposal of an associated company	(22.2)	-
Interest income	(19.9)	(40.2)
Reversal of provision for onerous contracts, net	(4.4)	(4.4)
(Gain)/loss on disposal of property, plant and equipment, net	(0.6)	0.5
Others	(1.1)	5.3
	<b>889.0</b>	<b>829.7</b>
Decrease/(increase) in working capital	77.0	(124.2)
Net cash generated from operations	966.0	705.5
Interest received	18.9	40.9
Interest paid	(223.0)	(202.3)
Taxes paid	(213.1)	(167.7)
<b>Net cash flows from operating activities</b>	<b>548.8</b>	<b>376.4</b>
Disposal of an associated company	148.4	-
Dividends received from associated companies	131.8	148.0
Deconsolidation of a discontinued operation	126.9	-
Decrease in restricted cash	24.0	3.6
Dividends received from financial assets at fair value through other comprehensive income	10.7	5.0
Decrease in short-term deposits with original maturity of more than three months	2.0	157.8
Disposal of property, plant and equipment	1.1	1.0
Investments in other intangible assets	(355.0)	(380.9)
Payments for purchase of property, plant and equipment	(212.8)	(128.8)
Investment in a joint venture	(147.5)	-
Acquisition of financial assets at fair value through other comprehensive income	(105.1)	(349.0)
Instalment payment for acquisition of a subsidiary company	(50.7)	(48.5)
Advances to joint ventures	(15.4)	-
Investments in biological assets	(5.1)	(4.5)
Increased investments in associated companies	(2.0)	(1.2)
Increased investments in joint ventures	(0.4)	(64.5)
Proceeds from an instalment payment for disposal of a subsidiary company	-	31.7
Disposal of financial assets at fair value through other comprehensive income	-	1.1
Disposal of investment properties	-	1.0
<b>Net cash flows used in investing activities</b>	<b>(449.1)</b>	<b>(628.2)</b>
Proceeds from new bank borrowings and other loans	3,175.9	1,329.3
Capital contributions from non-controlling shareholders	19.9	6.6
Repayment of bank borrowings and other loans	(2,989.2)	(956.8)
Dividends paid to non-controlling shareholders by subsidiary companies	(69.6)	(61.2)
Increased investments in subsidiary companies	(34.8)	(4.1)
Principal portion of lease payments	(14.4)	(16.8)
Payments for concession fees payable	(11.9)	(14.9)
Repurchase of shares	(7.5)	-
Payments for purchase of shares under a long-term incentive plan	(1.6)	(0.2)
Divestments of interests in subsidiary companies	-	92.1
Repurchase of shares by a subsidiary company	-	(13.9)
<b>Net cash flows from financing activities</b>	<b>66.8</b>	<b>360.1</b>
Net increase in cash and cash equivalents	166.5	108.3
Cash and cash equivalents at 1 January	2,363.2	2,650.8
Exchange translation	(51.0)	6.0
<b>Cash and cash equivalents at 30 June</b>	<b>2,478.7</b>	<b>2,765.1</b>
Representing		
Cash and cash equivalents and short-term deposits as stated in the condensed consolidated statement of financial position	2,638.0	2,801.6
Less: short-term deposits with original maturity of more than three months	(159.3)	(36.5)
<b>Cash and cash equivalents at 30 June</b>	<b>2,478.7</b>	<b>2,765.1</b>